Previous close | 0.0300 |
Open | 0.0300 |
Bid | 0.0280 x N/A |
Ask | 0.0300 x N/A |
Day's range | 0.0280 - 0.0300 |
52-week range | 0.0150 - 0.0660 |
Volume | |
Avg. volume | 1,730,362 |
Market cap | N/A |
Beta (5Y monthly) | 2.28 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0050 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Actinogen Medical Limited (ASX: ACW) announces that the first patient has been randomized and treated in the XanaMIA phase 2b clinical trial in patients with biomarker-positive mild to moderate Alzheimer's disease (AD). This represents the culmination of the site and screening setup phase of the trial when patient pre-screening for elevated levels of the pTau blood biomarker commenced at multiple clinical sites.
Actinogen Medical Limited ( ASX:ACW ) shareholders will doubtless be very grateful to see the share price up 50% in the...
Actinogen Medical Limited (ASX: ACW) announces that its human Positron Emission Tomography (PET) study, confirming high levels of Xanamem target occupancy in the brain at safe, well tolerated, and biologically active doses, has been published in the Journal of Alzheimer's Disease.